Uncategorized
OPUS-2: Lifitegrast improves symptoms but not signs of dry eye disease
BOSTON — Of two co-primary endpoints of the OPUS-2 study, signs and symptoms of dry eye disease, one was met and one was not, according to a speaker here. “The study robustly met the primary endpoint for symptom, with a P value of .0001; however, there was no statistically significant difference for the endpoint sign of corneal staining,” Joseph Tauber, MD, said at the American Society of Cataract and Refractive Surgery annual meeting.